- Home
- EGRX
as 07-26-2024 4:00pm EST
Eagle Pharmaceuticals Inc is a specialty pharmaceutical company. The company develops and commercializes injectable products in the areas of critical care, orphan diseases, and oncology. Its product portfolio consists of four approved products: Argatroban, Ryanodex, Belrapzo, and Bendeka. The company currently has multiple product candidates in advanced stages of development and is under review for approval by the Food and Drug Administration.
| Founded: | 2007 | Country: | United States |
| Employees: | N/A | City: | WOODCLIFF LAKE |
| Market Cap: | 74.4M | IPO Year: | 2014 |
| Target Price: | $17.00 | AVG Volume (30 days): | 247.3K |
| Analyst Decision: | Sell | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 0.91 | EPS Growth: | -48.59 |
| 52 Week Low/High: | $3.21 - $23.52 | Next Earning Date: | 08-06-2024 |
| Revenue: | $257,551,000 | Revenue Growth: | -5.38% |
| Revenue Growth (this year): | -16.77% | Revenue Growth (next year): | -18.13% |
Latest Eagle Pharmaceuticals Inc. News
EGRX Breaking Stock News: Dive into EGRX Ticker-Specific Updates for Smart Investing
MT Newswires
16 days ago
Eagle Pharmaceuticals Settles Disputes With Curia Global for $26.5 Million
GOBankingRates
2 months ago
5 Reasons a Biden Second Term Could Be a Financial Disaster for Boomers
AFP
2 months ago
Bumrah delivers as India beat Pakistan in low-scoring thriller
AFP
2 months ago
Italy beat Bosnia in final Euros warm-up
Bloomberg
2 months ago
Macron Calls French Legislative Election After Far-Right Surge
AFP
2 months ago
Trump loyalists proud to support 'felon' at Las Vegas rally
Business Insider
2 months ago
US solar producers could finally have a fighting chance as tariffs kick in on cheaper imports from Asia
Insider Monkey
2 months ago
The Best Woody Perfume For Women
Compare EGRX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "EGRX Eagle Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.